Results 141 to 150 of about 76,030 (307)

14‐3‐3σ up‐regulation in the temporal cortex associates with tau pathology and reactive astroglia in Lewy body disorders

open access: yesBrain Pathology, EarlyView.
14‐3‐3 protein homeostasis is disrupted in Lewy body pathology, showing a diminution of six isotypes and overexpression of stratifin. The latter was associated with stratifin colocalization with tau pathology and reactive astrocytes. Platelets, as a peripheral biomarker source, mirrored inversely cortical 14‐3‐3 gene expression patterns in dementia ...
Laura Marsal‐García   +13 more
wiley   +1 more source

Dopamine D2 Receptor Levels in Striatum, Thalamus, Substantia Nigra, Limbic Regions, and Cortex in Schizophrenic Subjects

open access: green, 2009
Robert Kessler   +8 more
openalex   +1 more source

Distinct regional patterns of synaptic vulnerability across hippocampal and parahippocampal subregions in Alzheimer's disease

open access: yesBrain Pathology, EarlyView.
Synaptic loss in Alzheimer's disease predominantly affects the entorhinal cortex and parahippocampal gyrus. Amyloid‐β and p‐tau pathology show global associations with synaptic density but are limited in specific subregions. Instead, axonal damage associates with synaptic loss locally and in interconnected subregions.
Maud M. A. Bouwman   +4 more
wiley   +1 more source

Helicobacter pylori infection and α-synuclein pathology drive parallel neurodegenerative pathways in the substantia nigra. [PDF]

open access: yesJ Neuroinflammation
Soto-Avellaneda A   +6 more
europepmc   +1 more source

Vesicular glutamate transporter VGLUT2 expression emerges in substantia nigra dopamine neurons in mouse models of parkinsonism in the absence of neurodegeneration

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Subsets of midbrain dopamine (DA) neurons express the vesicular glutamate transporter VGLUT2 and can release the excitatory neurotransmitter glutamate. VGLUT2+ DA neurons of the substantia nigra pars compacta (SNc) were shown to be more resistant to neurodegeneration in animal models of Parkinson's disease (PD ...
Sivakumar Srinivasan   +2 more
wiley   +1 more source

Matsupexole: A novel nonergot dopamine receptor agonist with sustained efficacy in a rat model of Parkinson's disease and limited off‐target activity

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Dopamine receptor agonists, particularly targeting the dopamine D2L receptor (D2LR), have been used to treat Parkinson's disease (PD). However, valvular heart disease and somnolence, mainly caused by activating the serotonin 5‐HT2B receptor (5‐HT2BR) and dopamine D3 receptor (D3R), respectively, currently challenge their clinical
Takayuki Suzuki   +4 more
wiley   +1 more source

Deep-learning segmentation of the substantia nigra from multiparametric MRI: Application to Parkinson's disease. [PDF]

open access: yesImaging Neurosci (Camb)
Lillebostad PAG   +11 more
europepmc   +1 more source

Dissociating role of Bassoon in glutamatergic and dopaminergic neurons in alcohol‐related behaviour and affective state in mice

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Alcohol abuse and affective disorders are severe comorbid psychiatric diseases characterized by impaired brain synaptic transmission. The role of presynaptic scaffolding proteins coordinating presynaptic plasticity and neurotransmitter release, such as Bassoon (Bsn), in the pathogenesis of these disorders remains elusive.
Liubov S. Kalinichenko   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy